Trofame XR (trospium) / Sun Pharma - LARVOL DELTA

Novel anti-psychotic shows promise in Phase II schizophrenia trial (European Pharmaceutical Review) - P2, N=182; EMERGENT-1 (NCT03697252); Sponsor: Karuna Therapeutics; "Dr Jeffrey Lieberman...a member of Karuna's scientific advisory board and co-author of the manuscript, added: 'The clinical trial results with KarXT highlight its potential to be a differentiated treatment option with a completely new mechanism of action for people living with schizophrenia, offering relief from acute psychotic symptoms without the debilitating side effects associated with the current standard of care.'"

Media quote • P2 data • Schizophrenia